BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 15480981)

  • 1. Celecoxib versus diclofenac plus omeprazole in high-risk arthritis patients: results of a randomized double-blind trial.
    Chan FK; Hung LC; Suen BY; Wong VW; Hui AJ; Wu JC; Leung WK; Lee YT; To KF; Chung SC; Sung JJ
    Gastroenterology; 2004 Oct; 127(4):1038-43. PubMed ID: 15480981
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Celecoxib versus diclofenac and omeprazole in reducing the risk of recurrent ulcer bleeding in patients with arthritis.
    Chan FK; Hung LC; Suen BY; Wu JC; Lee KC; Leung VK; Hui AJ; To KF; Leung WK; Wong VW; Chung SC; Sung JJ
    N Engl J Med; 2002 Dec; 347(26):2104-10. PubMed ID: 12501222
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Celecoxib versus omeprazole and diclofenac in patients with osteoarthritis and rheumatoid arthritis (CONDOR): a randomised trial.
    Chan FK; Lanas A; Scheiman J; Berger MF; Nguyen H; Goldstein JL
    Lancet; 2010 Jul; 376(9736):173-9. PubMed ID: 20638563
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Celecoxib compared with lansoprazole and naproxen to prevent gastrointestinal ulcer complications.
    Lai KC; Chu KM; Hui WM; Wong BC; Hu WH; Wong WM; Chan AO; Wong J; Lam SK
    Am J Med; 2005 Nov; 118(11):1271-8. PubMed ID: 16271912
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of celecoxib versus diclofenac and omeprazole in elderly arthritis patients: a subgroup analysis of the CONDOR trial.
    Kellner HL; Li C; Essex MN
    Curr Med Res Opin; 2012 Sep; 28(9):1537-45. PubMed ID: 22852870
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Primary prevention of diclofenac associated ulcers and dyspepsia by omeprazole or triple therapy in Helicobacter pylori positive patients: a randomised, double blind, placebo controlled, clinical trial.
    Labenz J; Blum AL; Bolten WW; Dragosics B; Rösch W; Stolte M; Koelz HR
    Gut; 2002 Sep; 51(3):329-35. PubMed ID: 12171952
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Economic analysis of celecoxib versus diclofenac plus omeprazole for the treatment of arthritis in patients at risk of ulcer disease.
    Lee KK; You JH; Ho JT; Suen BY; Yung MY; Lau WH; Lee VW; Sung JY; Chan FK
    Aliment Pharmacol Ther; 2003 Jul; 18(2):217-22. PubMed ID: 12869082
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Gastrointestinal safety of celecoxib versus naproxen in patients with cardiothrombotic diseases and arthritis after upper gastrointestinal bleeding (CONCERN): an industry-independent, double-blind, double-dummy, randomised trial.
    Chan FKL; Ching JYL; Tse YK; Lam K; Wong GLH; Ng SC; Lee V; Au KWL; Cheong PK; Suen BY; Chan H; Kee KM; Lo A; Wong VWS; Wu JCY; Kyaw MH
    Lancet; 2017 Jun; 389(10087):2375-2382. PubMed ID: 28410791
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study.
    Silverstein FE; Faich G; Goldstein JL; Simon LS; Pincus T; Whelton A; Makuch R; Eisen G; Agrawal NM; Stenson WF; Burr AM; Zhao WW; Kent JD; Lefkowith JB; Verburg KM; Geis GS
    JAMA; 2000 Sep; 284(10):1247-55. PubMed ID: 10979111
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Incidence of gastroduodenal ulcers during treatment with celecoxib or diclofenac: pooled results from three 12-week trials in Chinese patients with osteoarthritis or rheumatoid arthritis.
    Cheung R; Cheng TT; Dong Y; Lin HY; Lai K; Lau CS; Feng H; Parsons B
    Int J Rheum Dis; 2010 May; 13(2):151-7. PubMed ID: 20536600
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Eradication of Helicobacter pylori and risk of peptic ulcers in patients starting long-term treatment with non-steroidal anti-inflammatory drugs: a randomised trial.
    Chan FK; To KF; Wu JC; Yung MY; Leung WK; Kwok T; Hui Y; Chan HL; Chan CS; Hui E; Woo J; Sung JJ
    Lancet; 2002 Jan; 359(9300):9-13. PubMed ID: 11809180
    [TBL] [Abstract][Full Text] [Related]  

  • 12. COX-2-specific inhibitor or proton pump inhibitor plus traditional NSAID: is either approach sufficient for patients at highest risk of NSAID-induced ulcers?
    Cryer B
    Gastroenterology; 2004 Oct; 127(4):1256-8. PubMed ID: 15481002
    [No Abstract]   [Full Text] [Related]  

  • 13. Combination of a cyclo-oxygenase-2 inhibitor and a proton-pump inhibitor for prevention of recurrent ulcer bleeding in patients at very high risk: a double-blind, randomised trial.
    Chan FK; Wong VW; Suen BY; Wu JC; Ching JY; Hung LC; Hui AJ; Leung VK; Lee VW; Lai LH; Wong GL; Chow DK; To KF; Leung WK; Chiu PW; Lee YT; Lau JY; Chan HL; Ng EK; Sung JJ
    Lancet; 2007 May; 369(9573):1621-6. PubMed ID: 17499604
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Role of Helicobacter pylori in ulcer healing and recurrence of gastric and duodenal ulcers in longterm NSAID users. Response to omeprazole dual therapy.
    Bianchi Porro G; Parente F; Imbesi V; Montrone F; Caruso I
    Gut; 1996 Jul; 39(1):22-6. PubMed ID: 8881802
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Video capsule endoscopy to prospectively assess small bowel injury with celecoxib, naproxen plus omeprazole, and placebo.
    Goldstein JL; Eisen GM; Lewis B; Gralnek IM; Zlotnick S; Fort JG;
    Clin Gastroenterol Hepatol; 2005 Feb; 3(2):133-41. PubMed ID: 15704047
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Celecoxib versus diclofenac in long-term management of rheumatoid arthritis: randomised double-blind comparison.
    Emery P; Zeidler H; Kvien TK; Guslandi M; Naudin R; Stead H; Verburg KM; Isakson PC; Hubbard RC; Geis GS
    Lancet; 1999 Dec 18-25; 354(9196):2106-11. PubMed ID: 10609815
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anti-inflammatory and upper gastrointestinal effects of celecoxib in rheumatoid arthritis: a randomized controlled trial.
    Simon LS; Weaver AL; Graham DY; Kivitz AJ; Lipsky PE; Hubbard RC; Isakson PC; Verburg KM; Yu SS; Zhao WW; Geis GS
    JAMA; 1999 Nov; 282(20):1921-8. PubMed ID: 10580457
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reduced risk of upper gastrointestinal ulcer complications with celecoxib, a novel COX-2 inhibitor.
    Goldstein JL; Silverstein FE; Agrawal NM; Hubbard RC; Kaiser J; Maurath CJ; Verburg KM; Geis GS
    Am J Gastroenterol; 2000 Jul; 95(7):1681-90. PubMed ID: 10925968
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reduced incidence of gastroduodenal ulcers with celecoxib, a novel cyclooxygenase-2 inhibitor, compared to naproxen in patients with arthritis.
    Goldstein JL; Correa P; Zhao WW; Burr AM; Hubbard RC; Verburg KM; Geis GS
    Am J Gastroenterol; 2001 Apr; 96(4):1019-27. PubMed ID: 11316141
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Less small-bowel injury with lumiracoxib compared with naproxen plus omeprazole.
    Hawkey CJ; Ell C; Simon B; Albert J; Keuchel M; McAlindon M; Fortun P; Schumann S; Bolten W; Shonde A; Hugot JL; Yu V; Arulmani U; Krammer G; Rebuli R; Toth E
    Clin Gastroenterol Hepatol; 2008 May; 6(5):536-44. PubMed ID: 18242145
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.